Literature DB >> 17363705

Targeting CD47: NO limit on therapeutic potential.

David J Kaczorowski, Timothy R Billiar.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17363705     DOI: 10.1161/01.RES.0000261609.44977.25

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


× No keyword cloud information.
  4 in total

1.  Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces.

Authors:  Matthew J Finley; Lubica Rauova; Ivan S Alferiev; John W Weisel; Robert J Levy; Stanley J Stachelek
Journal:  Biomaterials       Date:  2012-05-20       Impact factor: 12.479

2.  CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.

Authors:  Kazumichi Yoshida; Hironori Tsujimoto; Kouji Matsumura; Manabu Kinoshita; Risa Takahata; Yusuke Matsumoto; Shuichi Hiraki; Satoshi Ono; Shuhji Seki; Junji Yamamoto; Kazuo Hase
Journal:  Cancer Med       Date:  2015-06-16       Impact factor: 4.452

3.  Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.

Authors:  Jinyun Bai; Mingfeng Xia; Yaqian Xue; Fengguang Ma; Aoyuan Cui; Yixuan Sun; Yamei Han; Xi Xu; Feifei Zhang; Zhimin Hu; Zhengshuai Liu; Yuxiao Liu; Genxiang Cai; Weitong Su; Xiaoyang Sun; Haifu Wu; Hongmei Yan; Xinxia Chang; Xiqi Hu; Hua Bian; Pu Xia; Jing Gao; Yu Li; Xin Gao
Journal:  EBioMedicine       Date:  2020-06-21       Impact factor: 8.143

Review 4.  Engineered Cell Membrane-Derived Nanoparticles in Immune Modulation.

Authors:  Yixiao Yang; Kai Wang; Yuanwei Pan; Lang Rao; Gaoxing Luo
Journal:  Adv Sci (Weinh)       Date:  2021-10-24       Impact factor: 16.806

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.